Skip To Content
+1-866-963-9975

This official website is maintained by the Notice Administrator supervised by Class Counsel in the Class Action titled CareFirst of Maryland, Inc. et al. v. Johnson & Johnson, et al., No. 2:23-cv-00629-JKW-LRL (the “Action”) pending in the United States District Court for the Eastern District of Virginia.

Stelara TPP Class Action Lawsuit

If you purchased or paid some or all of the purchase price of Stelara, a class action lawsuit may affect your rights.

The information contained on this web page is only a summary of information presented in more detail in the Long-Form Notice (“Notice”). Since this website is just a summary, you should review the Notice for additional information.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS LAWSUIT
Description Due Date

DO NOTHING

If you are a member of the Class, by doing nothing, you will remain in the Class and may be entitled to share in any recovery that may come from a trial or settlement with the Defendants for the Class. You will be bound by any Court decision in this lawsuit (including a judgment in favor of the Defendants) as to the Class, and you will give up your rights to sue any of the Defendants about the same set of facts, series of transactions, or legal claims involved in this lawsuit as to the Class.

EXCLUDE YOURSELF FROM THE CLASS

This is the only option that allows you to file or be part of another lawsuit against the Defendants relating to the claims in this case.


If you are a member of the Class, you may exclude yourself from the Class. You will not be bound by any of the Court’s orders in this case if you exclude yourself. If you exclude yourself from the Class, you will keep your right to sue Defendants for the Class’s claims against the Defendants, but you will not be entitled to participate in and benefit from a recovery, if any, on behalf of the Class.


Any dispute about your request to be excluded will be resolved by the Court.


The deadline to exclude yourself from the lawsuit is January 22, 2026.

GET MORE INFORMATION

If you would like more information about the lawsuit, you can review this Notice and send questions to the Plaintiffs’ lawyers identified in Question 13 of the Notice.

DO NOT CONTACT THE COURT OR THE DEFENDANTS IF YOU HAVE QUESTIONS REGARDING THIS NOTICE.

What is the lawsuit about?

Plaintiffs CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc., and CareFirst Bluechoice, Inc. (together, “CareFirst”, the “CareFirst Plaintiffs” or “Plaintiffs”) filed a lawsuit individually and as representative of all persons or entities in the Class.

The lawsuit alleges that the Defendants engaged in a scheme in violation of state antitrust and consumer protection laws. J&J knowingly, willfully, and improperly maintained its monopoly power and substantially reduced and harmed competition in the market for ustekinumab in the United States by: (1) fraudulently obtaining a method-of-use patent to treat ulcerative colitis, (2) wrongfully acquiring the Momenta biosimilar manufacturing patents, and then (3) asserting and/or enforcing those patents (the ’307 and Momenta patents) against would-be competitors to unlawfully delay biosimilar competition. Defendants’ scheme delayed the entry of biosimilar competition for J&J’s brand name prescription pharmaceutical drug Stelara by at least fifteen months.

The lawsuit asserts that, as a result of J&J’s alleged unlawful conduct, the prices TPPs paid for the at-issue drugs were higher than they otherwise would have been. Plaintiffs seek to recover damages in the form of overcharges they allege were caused by Defendants’ conduct. Plaintiffs also seek to recover attorneys’ fees and litigation costs.

Defendants deny all these allegations, including that Plaintiffs or members of the Class are entitled to damages or other relief. The Court has not decided whether the Plaintiffs or Defendants are right. The lawyers for the Plaintiffs will have to prove their claims in Court.

Further Information:

The information contained on this web page is only a summary of information presented in more detail in the Long-Form Notice (“Notice”). Since this website is just a summary, you should review the Notice for additional information.